Type IV phosphodiesterase inhibitor suppresses insulin-dependent myocardial glucose uptake

Kenichi Imahashi, Jun Yoshioka, Tsuyoshi Yamakita, Suzuyo Yamano, Hideo Kusuoka, Tsunehiko Nishimura

Research output: Contribution to journalArticlepeer-review

2 Scopus citations


1. Phosphodiesterase (PDE) IV has been localized at cardiomyocytes and the coronary vasculature and modulates cAMP, but the effect of PDE IV on myocardial glucose uptake has not been demonstrated. 2. Glucose uptake in rat isolated hearts treated with the PDE IV inhibitor rolipram was measured by [31P] nuclear magnetic resonance spectroscopy. 3. Under non-stimulating conditions, glucose uptake was not significantly different between control and rolipram (1 μmol/L)-treated rat hearts, whereas enhanced uptake in insulin-stimulated conditions was significantly attenuated by rolipram. 4. Phosphodiesterase IV inhibitor negatively affects insulin-dependent myocardial glucose uptake.

Original languageEnglish (US)
Pages (from-to)290-291
Number of pages2
JournalClinical and Experimental Pharmacology and Physiology
Issue number4
StatePublished - 2001
Externally publishedYes


  • Heart
  • Insulin
  • Magnetic resonance spectroscopy

ASJC Scopus subject areas

  • Physiology
  • Pharmacology
  • Physiology (medical)


Dive into the research topics of 'Type IV phosphodiesterase inhibitor suppresses insulin-dependent myocardial glucose uptake'. Together they form a unique fingerprint.

Cite this